ArticleProceedings of the National Academy of Sciences of the United States of America2017
Selective in vivo removal of pathogenic anti-MAG autoantibodies, an antigen-specific treatment option for anti-MAG neuropathy.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 48 citations in OpenAlex.
- Using Synthetic Glycans to Investigate Anti-Glycan Antibodies and Explore Their Medical Potential.Angewandte Chemie (International ed. in English) · 2026Review
- Glycopolymer binds pathogenic IgM autoantibodies and pulls them into the mononuclear phagocyte system for degradation.Scientific reports · 2025Article
- Expediting Glycospace Exploration: Therapeutic Glycans via Automated Synthesis.Angewandte Chemie (International ed. in English) · 2025Review
- The prevalence of IgG antibodies against milk and milk antigens in patients with multiple sclerosis.Frontiers in immunology · 2023Article
- Value of Antibody Determinations in Chronic Dysimmune Neuropathies.Brain sciences · 2022Review
- Selective Capture of Anti-N-glucosylated NTHi Adhesin Peptide Antibodies by a Multivalent Dextran Conjugate.Chembiochem : a European journal of chemical biology · 2022Article
- Emerging Role of Neuron-Glia in Neurological Disorders: At a Glance.Oxidative medicine and cellular longevity · 2022Review
- Review
- Emerging glyco-based strategies to steer immune responses.The FEBS journal · 2021Review
- CGRP-Mediated Prolactin Upregulation: a Possible Pathomechanism in IgG4-Related Disease.Inflammation · 2021Article
- Paraneoplastic Neuropathies: What's New Since the 2004 Recommended Diagnostic Criteria.Frontiers in neurology · 2021Review
- Synthetic linear glycopolymers and their biological applications.Journal of carbohydrate chemistry · 2021Article
- Article
- Selective inhibition of anti-MAG IgM autoantibody binding to myelin by an antigen-specific glycopolymer.Journal of neurochemistry · 2020Article
- From Anti-EBV Immune Responses to the EBV Diseasome via Cross-reactivity.Global medical genetics · 2020Article
- Anti-MAG IgM: differences in antibody tests and correlation with clinical findings.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2020Article
- The complement system in liver diseases: Evidence-based approach and therapeutic options.Journal of translational autoimmunity · 2019Review
- Relevance of anti-HNK1 antibodies in the management of anti-MAG neuropathies.Journal of neurology · 2019Article
- Peripheral Demyelinating Diseases: From Biology to Translational Medicine.Frontiers in neurology · 2019Review
- Individualized immunoglobulin therapy in chronic immune-mediated peripheral neuropathies.Journal of the peripheral nervous system : JPNS · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-MAG (myelin-associated glycoprotein) neuropathy is a disabling autoimmune peripheral neuropathy caused by monoclonal IgM autoantibodies that recognize the carbohydrate epitope HNK-1 (human natural killer-1). This glycoepitope is highly expressed on adhesion molecules, such as MAG, present in myelinated nerve fibers. Because the pathogenicity and demyelinating properties of anti-MAG autoantibodies are well established, current treatments are aimed at reducing autoantibody levels. However, current therapies are primarily immunosuppressive and lack selectivity and efficacy. We therefore hypothesized that a significant improvement in the disease condition could be achieved by selectively neutralizing the pathogenic anti-MAG antibodies with carbohydrate-based ligands mimicking the natural HNK-1 glycoepitope 1. In an inhibition assay, a mimetic (2, mimHNK-1) of the natural HNK-1 epitope blocked the interaction of MAG with pathogenic IgM antibodies from patient sera but with only micromolar affinity. Therefore, considering the multivalent nature of the MAG-IgM interaction, polylysine polymers of different sizes were substituted with mimetic 2. With the most promising polylysine glycopolymer PL
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.